capsule
Tesofensine
emergingPhase 2/3 Clinical TrialsOral
Originally for Parkinson's/Alzheimer's, found to cause major weight loss. Boosts serotonin, dopamine, and norepinephrine simultaneously, crushing appetite and revving metabolism.
Key facts
- Classification
- Tesofensine is a triple monoamine reuptake inhibitor (5-HT, NE, DA).
- Primary benefits
- Fat Loss (7/10) · Brain & Cognition (4/10) · Mood & Anxiety (3/10)
- Administration
- Oral
- Doses studied
- 0.25-0.5 mg by mouth daily. Start at the lower dose. Cycle for 12-24 weeks.
- Evidence strength
- Emerging — 20 peer-reviewed studies
- Stacks well with
- Semaglutide, 5-Amino-1MQ
- Legal status
- Phase 2/3 Clinical Trials · not prescribable in US
Quick stats
- Type
- Capsule
- Administration
- Oral
- Studies referenced
- 20
- Stacks with
- 2 peptides
- Regulatory
- Phase 2/3 Clinical Trials
Scientific overview
Tesofensine is a triple monoamine reuptake inhibitor (5-HT, NE, DA). Phase 2 obesity trials showed 4.5-10.6% weight loss over 24 weeks via central appetite suppression and thermogenesis. Requires cardiovascular monitoring due to modest HR and BP increases.
Goal coverage · Tesofensine
🔥 Fat Loss7/10
🧠 Brain & Cognition4/10
😌 Mood & Anxiety3/10
Medical oversight requiredNot safe during pregnancy· 7 contraindications